Related Experiment Video
Updated: Nov 12, 2025
A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation
Published on: June 10, 2020
The second phase of brain trauma can be controlled by nutraceuticals that suppress DAMP-mediated microglial
Mark F McCarty1, Aaron Lerner2
1Department of research, Catalytic Longevity Foundation, San Diego, California, USA.
Introduction:
A delayed second wave of brain trauma is mediated in large part by microglia that are activated to a pro-inflammatory M1 phenotype by DAMP proteins released by dying neurons. These microglia can promote apoptosis or necrosis in neighboring neurons by producing a range of pro-inflammatory cytokines and the deadly oxidant peroxynitrite. This second wave could therefore be mitigated with agents that blunt the post-traumatic M1 activation of microglia and that preferentially promote a pro-healing M2 phenotype.
Areas Covered:
The literature on nutraceuticals that might have clinical potential in this regard.
Expert Opinion:
The chief signaling pathway whereby DAMPs promote M1 microglial activation involves activation of toll-like receptor 4 (TLR4), NADPH oxidase, NF-kappaB, and the stress activated kinases JNK and p38. The green tea catechin EGCG can suppress TLR4 expression. Phycocyanobilin can inhibit NOX2-dependent NADPH oxidase, ferulate and melatonin can oppose pro-inflammatory signal modulation by NADPH oxidase-derived oxidants. Long-chain omega-3 fatty acids, the soy isoflavone genistein, the AMPK activator berberine, glucosamine, and ketone bodies can down-regulate NF-kappaB activation. Vitamin D activity can oppose JNK/p38 activation. A sophisticated program of nutraceutical supplementation may have important potential for mitigating the second phase of neuronal death and aiding subsequent healing.
Insights
Nutraceuticals show promise in mitigating the secondary brain injury wave. Compounds like EGCG, phycocyanobilin, and omega-3 fatty acids target microglial M1 activation, promoting healing.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- A delayed second wave of brain trauma involves microglia activation to a pro-inflammatory M1 phenotype by damage-associated molecular patterns (DAMPs).
- These activated microglia release pro-inflammatory cytokines and peroxynitrite, causing neuronal apoptosis or necrosis.
- Mitigating this secondary wave requires agents that reduce M1 activation and promote a pro-healing M2 microglial phenotype.
Purpose of the Study:
- To review the literature on nutraceuticals with potential clinical applications for mitigating the secondary wave of brain injury.
- To identify specific compounds and their mechanisms of action in modulating microglial activation pathways.
Main Methods:
- Literature review of studies on nutraceuticals targeting microglial activation pathways.
- Analysis of signaling pathways involved in DAMP-induced M1 microglial activation, including TLR4, NADPH oxidase, NF-kappaB, JNK, and p38.
- Identification of specific nutraceuticals and their effects on these pathways.
Main Results:
- Epigallocatechin gallate (EGCG) suppresses toll-like receptor 4 (TLR4) expression.
- Phycocyanobilin inhibits NOX2-dependent NADPH oxidase; ferulate and melatonin oppose NADPH oxidase-derived oxidants.
- Omega-3 fatty acids, genistein, berberine, glucosamine, and ketone bodies down-regulate NF-kappaB; Vitamin D opposes JNK/p38 activation.
Conclusions:
- A targeted nutraceutical supplementation program can potentially mitigate the secondary phase of neuronal death after brain trauma.
- These agents may help promote subsequent healing by modulating microglial phenotype and reducing neuroinflammation.
